Literature DB >> 1287420

Determination of IgG subclass antibodies to Pseudomonas aeruginosa outer membrane proteins in cystic fibrosis lung infection using immunoblotting and enzyme-linked immunosorbent assay.

T Pressler1, G Kronborg, G H Shand, B Mansa, N Høiby.   

Abstract

IgG subclass antibodies to Pseudomonas aeruginosa outer membrane proteins (OMP) were investigated in serum from cystic fibrosis (CF) patients by immunoblotting and enzyme-linked immunosorbent assay (ELISA). Fifteen patients (eight in good and seven in poor clinical condition) have been followed for an average of 13 years with multiple serum samples covering the preinfection, and early and late stages of chronic infection. Laser-scanning densitometry of photographs taken from immunoblots was used to quantify antibody level and compare with ELISA titres. The earliest anti-OMP antibodies to appear were of the IgG1 subclass. There was no significant difference in IgG subclass antibody levels to OMPs between patients in relatively good and poor clinical condition. Data presented indicate a high positive correlation among measurements of IgG subclass antibodies to P. aeruginosa OMPs using ELISA and immunoblotting.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287420     DOI: 10.1007/bf00191546

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  26 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

Review 2.  IgG subclass distribution of antibodies to bacterial and viral antigens.

Authors:  A Ferrante; L J Beard; R G Feldman
Journal:  Pediatr Infect Dis J       Date:  1990-08       Impact factor: 2.129

3.  Prevalence and persistence of polyagglutinable Pseudomonas aeruginosa in isolates from cystic fibrosis patients.

Authors:  B Ojeniyi; N Høiby; V T Rosdahl
Journal:  APMIS       Date:  1991-02       Impact factor: 3.205

4.  Immunoglobulin-G subclasses in cystic fibrosis. IgG2 response to Pseudomonas aeruginosa lipopolysaccharide.

Authors:  R B Fick; J Olchowski; S U Squier; W W Merrill; H Y Reynolds
Journal:  Am Rev Respir Dis       Date:  1986-03

Review 5.  IgG4 and the immune system.

Authors:  L Perelmutter
Journal:  Clin Rev Allergy       Date:  1983-06

6.  Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; B Dinesen; G H Shand; T Pressler; N Høiby
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

7.  Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodium-lauryl sarcosinate.

Authors:  C Filip; G Fletcher; J L Wulff; C F Earhart
Journal:  J Bacteriol       Date:  1973-09       Impact factor: 3.490

8.  The binding of human and guinea-pig IgG subclasses to homologous macrophage and monocyte Fc receptors.

Authors:  M D Alexander; J A Andrews; R G Leslie; N J Wood
Journal:  Immunology       Date:  1978-07       Impact factor: 7.397

9.  Serum IgG antibody to outer membrane antigens of Pseudomonas cepacia and Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S C Aronoff; R C Stern
Journal:  J Infect Dis       Date:  1988-05       Impact factor: 5.226

10.  Increased levels of IgG subclasses specific for Pseudomonas aeruginosa exoenzyme and polysaccharide antigens in chronically infected patients with cystic fibrosis.

Authors:  A Albus; M Saalmann; H Tesch; S S Pedersen; G Döring
Journal:  APMIS       Date:  1989-12       Impact factor: 3.428

View more
  1 in total

1.  Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.

Authors:  Ryka Moore; Jennelle M Kyd; Rosemary Carzino; Davide Armstrong; Keith Grimwood; Diana C Otczyk; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2012-12-18       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.